Climb BioCLYM -0.91%22 Quick Ratio is 27.86 as of Mar. 2026, which is 14% above its 10-year median of 24.45. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Climb Bio ranks better than 95.9% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Climb Bio's quick ratio for the quarter that ended in Mar. 2026 was 27.86.
Climb Bio has a quick ratio of 27.86. It generally indicates good short-term financial strength.
The historical rank and industry rank for Climb Bio's Quick Ratio or its related term are showing as below:
CLYM'
s Quick Ratio Range Over the Past 10 Years
Min: 7.18 Med: 24.45 Max: 60.41
Current: 27.86
During the past 7 years, Climb Bio's highest Quick Ratio was 60.41. The lowest was 7.18. And the median was 24.45.
CLYM's Quick Ratio is ranked better than 95.9% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs CLYM: 27.86
Climb Bio (NAS:CLYM) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Climb Bio Quick Ratio Related Terms
Climb Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for Climb Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Climb Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Climb Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Climb Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Climb Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Climb Bio's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Climb Bio (CLYM) has a Quick Ratio of 27.86 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Climb Bio and its competitors. This is 14% above median its historical median of 24.45. Over the past decade, Climb Bio's Quick Ratio has ranged from 7.18 to 60.41. According to the industry distribution chart, Climb Bio ranks #58 out of 1416 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Climb Bio's Quick Ratio too high?
Climb Bio's current Quick Ratio of 27.86 is 14% above median its 10-year median of 24.45. Over the past 10 years, this metric has ranged from a low of 7.18 to a high of 60.41. The Biotechnology industry median Quick Ratio is 3.60. Climb Bio's value of 27.86 is 673.9% above this industry median. Based on the distribution chart, Climb Bio ranks #58 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Quick Ratio compare to ACRS and CABA?
According to the Biotechnology industry distribution chart, Climb Bio ranks #58 out of 1416 companies for Quick Ratio. This places Climb Bio in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Climb Bio's value of 27.86 is 673.9% above this benchmark. Historically, Climb Bio's own Quick Ratio has ranged from 7.18 to 60.41 over the past decade. While the company's 10-year median is 24.45 vs. the industry median of 3.60, Climb Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Climb Bio's current Quick Ratio of 27.86 is 673.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Climb Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current Quick Ratio is 27.86, which is 14% above median its own 10-year median of 24.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Quick Ratio of 27.86. The current Quick Ratio is 27.86, which is 14% above median its 10-year median of 24.45 and 673.9% above the Biotechnology industry median of 3.60. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Climb Bio (CLYM), the current Quick Ratio is 27.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score
Get the complete analysis for CLYM
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYM has been successfully added to your 
